BC ARTHRITIS STRENGTH

Compare BC ARTHRITIS STRENGTH  to:
Compare
Compare

Generic Name for BC ARTHRITIS STRENGTH

Aspirin 742mg, caffeine 38mg, salicylamide 222mg; per powder; contains potassium 65mg/powder.

Legal Classification:

OTC

Pharmacological Class for BC ARTHRITIS STRENGTH

Salicylate.

Manufacturer of BC ARTHRITIS STRENGTH

GlaxoSmithKline Pharmaceuticals

Indications for BC ARTHRITIS STRENGTH

Minor arthritis pain.

Adult dose for BC ARTHRITIS STRENGTH

Place powder on tongue and follow with liquid; or may stir into glass of water or other liquids. 1 powder every 3–4 hours; max: 4 powders/24 hours.

Children's dosing for BC ARTHRITIS STRENGTH

Not recommended.

Contraindications for BC ARTHRITIS STRENGTH

NSAID allergy. Viral infection in children and teenagers. 3rd trimester pregnancy.

Warnings/Precautions for BC ARTHRITIS STRENGTH

History of asthma or peptic ulcer. Severe hepatic or renal dysfunction. Bleeding disorders. Diabetes. Gout. Pregnancy. Nursing mothers: not recommended.

Interactions for BC ARTHRITIS STRENGTH

Potentiates anticoagulants, hypoglycemics, methotrexate, acetazolamide, valproic acid, highly protein-bound drugs. Urinary alkalinizers, antacids, corticosteroids may increase excretion. May antagonize ACE inhibitors, β-blockers, diuretics, uricosurics. Increased bleeding risk with NSAIDs or chronic, heavy alcohol use. NSAIDs increase risk of renal dysfunction. Additive effects with other caffeine-containing products.

Adverse Reactions for BC ARTHRITIS STRENGTH

GI upset/bleed, prolonged bleeding time, anaphylaxis, salicylism.

How is BC ARTHRITIS STRENGTH supplied?

Powder—6, 24, 50

Related Disease:

Arthritis~NSAIDs

Related Resources

Arava Boxed Warning updated to include severe liver injury

July 13, 2010

The FDA has updated the Boxed Warning of Arava (leflunomide, from sanofi aventis) to highlight the risk of severe liver injury in patients using this drug and how this risk may be reduced.

Phase 3 study of Lodotra for the treatment of rheumatoid arthritis (RA)

June 17, 2010

Horizon Pharma announced that data from its Phase 3 study of Lodotra showed a statistically significant improvement in American College of Rheumatology (ACR) response criteria in patients with rheumatoid arthritis (RA).

Phase 3 trial of Lodotra for rheumatoid arthritis

June 16, 2010

Horizon Pharma announced positive results from its Phase 3 registration study of Lodotra (prednisone tablet), that showed a statistically significant improvement in American College of Rheumatology (ACR) response criteria in patients with rheumatoid arthritis (RA).

FDA accepts NDA for Duexa for ulcer risk reduction in arthritis patients

May 26, 2010

Horizon Pharma announced that its New Drug Application (NDA) for Duexa was accepted by the FDA for the reduction of the risk of development of upper gastrointestinal ulcers in patients with arthritis and pain.

Salonpas Pain Relief Patch and Salonpas Arthritis Pain patch available

May 24, 2010

Hisamitsu announced the launch of Salonpas Pain Relief Patch (10% methyl salicylate and 3% I-menthol) and Salonpas Arthritis Pain patch (10% methyl salicylate and 3% I-menthol) for the temporary relief of mild to moderate aches and pains of the muscles and joints associated with arthritis, sprains, strains, bruises and simple backaches experienced by patients age ≥18 years.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions